Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11306662 | 0.81 | TYR (0.48) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL2902317 | 0.81 | TYR (0.74) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL5694354 | 0.80 | EGFR (0.50) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL51397 | 0.79 | TYR (0.71) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL1397158 | 0.79 | TYR (1.00) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL647503 | 0.77 | TYR (0.68) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL10942834 | 0.76 | HSD17B10 (0.52) | TYRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL3210936 | 0.76 | POLB (0.57) | TYRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL785775 | 0.75 | TYR (0.65) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL4370686 | 0.75 | TYR (0.81) | TYRALOX5MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1493593-B1 | Thermal transfer recording system having an amorphous dye phase | POLAROID CORP (US) | 2006-05-31 | — | — | EP | disclosed |
| CN-1694700-A | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-11-09 | — | — | CN | disclosed |
| EP-1493593-A1 | Thermal transfer recording system having an amorphous dye phase | Polaroid Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1263607-A1 | THERMAL TRANSFER RECORDING SYSTEM HAVING AN AMORPHOUS DYE PHASE | POLAROID CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| CN-1376143-A | Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES (JP) | 2002-10-23 | — | — | CN | disclosed |
| EP-1209147-A1 | CARBOXYLIC ACID DERIVATIVES AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-20010043239-A1 | Thermal transfer recording system | MOROOD INTERNATIONAL, SPC (SA) | 2001-11-22 | — | — | US | disclosed |
| WO-2001056805-A1 | THERMAL TRANSFER RECORDING SYSTEM HAVING AN AMORPHOUS DYE PHASE | POLAROID CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | TYR 84/4885ALOX5 711/4885MEN1 3690/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | TYR 108/4885ALOX5 4130/4885MEN1 1767/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | TYR 86/4885ALOX5 769/4885MEN1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.